CORT — Corcept Therapeutics Incorporated Share News
0.000.00%
Last trade - 00:00- $12.26bn
- $11.94bn
- $761.41m
Live Markets: US earnings forecast jumps further after key reports this week
Live Markets: Who's next for the S&P 500? The clock is ticking
U.S. RESEARCH ROUNDUP-Equinix, Meta, S&P Global
Corcept Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Corcept Therapeutics Q2 revenue estimates, raises 2026 outlook
Brief: Corcept Therapeutics Q2 EPS USD 0.36
U.S. RESEARCH ROUNDUP-Boeing, Coca-Cola, PayPal
Brief: Corcept Therapeutics To Announce Second Quarter Financial Results
Brief: Corcept Resubmits New Drug Application For Relacorilant As A Treatment For Patients With Cushing’s Syndrome
U.S. RESEARCH ROUNDUP-Salesforce, Snowflake, Zscaler
Brief: Corcept To Resubmit NDA For Relacorilant As Treatment For Cushing's Syndrome Patients
U.S. RESEARCH ROUNDUP- Caterpillar, Textron, Wesco International
Corcept Q1 revenue rises but misses analyst estimates
Brief: Corcept Therapeutics Q1 EPS USD -0.3
U.S. STOCKS ON THE MOVE-ADMA Biologics, Nanobiotix, DraftKings
Corcept Therapeutics shares surge as lead drug gets FDA nod for ovarian cancer (updated)
Corcept rises after FDA approves ovarian cancer drug
US FDA approves Corcept Therapeutics' drug for hard-to-treat ovarian cancer
Brief: FDA Approves Relacorilant With NAB-Paclitaxel For Platinum-Resistant Epithelial Ovarian, Fallopian Tube,Primary Peritoneal Cancer